Coste-efectividad y seguridad de telaprevir y boceprevir para el tratamiento de la hepatitis C crónica en la práctica clínica-Reference-Cited by-同舟云学术

Coste-efectividad y seguridad de telaprevir y boceprevir para el tratamiento de la hepatitis C crónica en la práctica clínica

Published:2015-12 Issue:10 Volume:38 Page:575-582
ISSN:0210-5705
Container-title:Gastroenterología y Hepatología
language:es
Short-container-title:Gastroenterología y Hepatología

Author:

Giménez-Manzorro Álvaro,García-González Xandra,Rodríguez-González Carmen Guadalupe,Ochoa-Palominos Alejandra,Sanjurjo-Sáez María,Clemente-Ricote Gerardo

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference28 articles.

1. Evolving epidemiology of hepatitis C virus;Lavanchy;Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis.,2011

2. Rantala M, van de Laar M. Surveillance and epidemiology of hepatitis B and C in Europe, a review. Eur Surveill [Internet] 2008;13(21) [consultado 25 Jun 2014]. Disponible en: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=18880

3. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: Updated criteria and genotype assignment web resource;Smith;Hepatol Baltim Md.,2014

4. Acute hepatitis C in HIV-infected men who have sex with men: An emerging sexually transmitted infection;Van de Laar;AIDS Lond Engl.,2010

5. The changing epidemiology of hepatitis C virus infection in Europe;Esteban;J Hepatol.,2008

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical and economic value of sofosbuvir-based regimens in the treatment of chronic hepatitis C in Spain;PLOS ONE;2022-12-01

2. Economic Evaluations Informed Exclusively by Real World Data: A Systematic Review;International Journal of Environmental Research and Public Health;2020-02-12

3. Outcomes of treatment with direct-acting antivirals for infection with hepatitis C virus genotypes 1–4 in an ambulatory care setting;American Journal of Health-System Pharmacy;2017-03-01

4. The era of first direct-acting antiviral agents: What did we learn?;Clinical Liver Disease;2016-09

5. Efficacy and direct costs of chronic hepatitis C treatment with first generation NS3/4A protease inhibitors in a real life population;Clinical and Experimental Hepatology;2016